Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-A1811 + trastuzumab + pyrotinib + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral (pyrotinib)
01
Overview
A four-drug combination regimen consisting of SHR-A1811 (an anti-HER2 antibody-drug conjugate), trastuzumab (a humanized IgG1 monoclonal antibody targeting HER2), pyrotinib (an oral irreversible pan-ErbB receptor tyrosine kinase inhibitor), and nab-paclitaxel (nanoparticle albumin-bound formulation of paclitaxel). The combination is designed to target HER2-positive or HER2-altered cancers, such as breast and lung cancer, by leveraging multiple mechanisms: direct HER2 targeting, receptor blockade, kinase inhibition, and microtubule disruption. SHR-A1811 delivers cytotoxic agents specifically to HER2-expressing cells via antibody-drug conjugate technology. Trastuzumab blocks HER2-mediated signaling and mediates antibody-dependent cellular cytotoxicity. Pyrotinib inhibits downstream signaling by irreversibly binding HER2 and EGFR family kinases. Nab-paclitaxel disrupts microtubule dynamics, inhibiting cell division. The regimen is under investigation in clinical trials for HER2-positive and HER2-mutant solid tumors[1][2][3][7].
- Brand names
- Airuini
- Other names
- SHR-A1811 ADCSHR-A-1811 ADCSHR-A 1811 ADCtrastuzumab IVtrastuzumab SCpyrotinib maleatenanoparticle albumin-bound paclitaxel
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on SHR-A1811 + trastuzumab + pyrotinib + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-A1811 + trastuzumab + pyrotinib + nab-paclitaxel.